Selectively targeting mutant BRAF in thyroid cancer.
作者信息
Ball Douglas W
出版信息
J Clin Endocrinol Metab. 2010 Jan;95(1):60-1. doi: 10.1210/jc.2009-2332.
Abstract
摘要
相似文献
1
Selectively targeting mutant BRAF in thyroid cancer.选择性靶向甲状腺癌中的突变BRAF
J Clin Endocrinol Metab. 2010 Jan;95(1):60-1. doi: 10.1210/jc.2009-2332.
2
Clinical implications of BRAF mutation in thyroid carcinoma.BRAF突变在甲状腺癌中的临床意义。
Trends Endocrinol Metab. 2008 May-Jun;19(4):138-45. doi: 10.1016/j.tem.2007.12.003. Epub 2008 Mar 11.
3
Therapeutic breakthroughs for metastatic thyroid cancer.转移性甲状腺癌的治疗突破。
Nat Rev Endocrinol. 2020 Feb;16(2):77-78. doi: 10.1038/s41574-019-0307-2.
4
BRAF as a target for cancer therapy.BRAF 作为癌症治疗的靶点。
Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. doi: 10.2174/187152011795347469.
5
Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.BRAF 抑制通过增强 tsMHCII 介导的免疫识别使甲状腺癌对免疫治疗敏感。
J Clin Endocrinol Metab. 2021 Jan 1;106(1):91-107. doi: 10.1210/clinem/dgaa656.
6
Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.在BRAF V600E乳头状甲状腺癌模型中，长期维莫非尼治疗通过KRAS G12D自发突变导致抑制剂耐药。
Oncotarget. 2016 May 24;7(21):30907-23. doi: 10.18632/oncotarget.9023.
7
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.RAS/RAF/ERK 信号通路的激活导致甲状腺癌细胞系对舒尼替尼产生耐药性。
J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.
8
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.维莫非尼用于放射性碘难治性BRAF（V600E）阳性转移性或不可切除性乳头状甲状腺癌患者：一项非随机、多中心、开放标签的2期试验。
Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.
9
Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF Mutated Papillary Thyroid Cancer: Two Case Reports.达拉非尼和曲美替尼间歇性给药治疗转移性 BRAF 突变型甲状腺乳头状癌：两例病例报告。
Thyroid. 2017 Sep;27(9):1201-1205. doi: 10.1089/thy.2017.0106.
10
Vemurafenib Active in Iodine-Refractory Thyroid Cancer.维莫非尼在碘难治性甲状腺癌中有效。
Cancer Discov. 2016 Oct;6(10):OF4. doi: 10.1158/2159-8290.CD-NB2016-105. Epub 2016 Aug 23.
引用本文的文献
1
Vitamin C sensitizes BRAF thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032.维生素 C 通过抑制 PLX4032 对 MAPK/ERK 信号的反馈激活，使 BRAF 甲状腺癌对 PLX4032 敏感。
J Exp Clin Cancer Res. 2021 Jan 19;40(1):34. doi: 10.1186/s13046-021-01831-y.
2
Activating BRAF mutation in sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: two case reports and review of the literature.甲状腺嗜酸性硬化性黏液表皮样癌中的BRAF激活突变：两例病例报告及文献复习
J Med Case Rep. 2019 Dec 28;13(1):385. doi: 10.1186/s13256-019-2288-0.
3
A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.免疫组织化学和分子方法相结合可提高甲状腺乳头状癌中BRAF突变的高灵敏度检测。
Endocrine. 2016 Sep;53(3):672-80. doi: 10.1007/s12020-015-0720-9. Epub 2015 Aug 22.
4
Molecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker?甲状腺乳头状癌中线粒体ATP酶亚基基因表达的分子分析：ATP5E转录本是否可能成为早期肿瘤标志物？
Med Sci Monit. 2015 Jun 16;21:1745-51. doi: 10.12659/MSM.893597.
5
Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.BRAF V600E突变在甲状腺乳头状癌中的预后价值。
Oncol Lett. 2014 Feb;7(2):439-443. doi: 10.3892/ol.2013.1713. Epub 2013 Nov 29.
6
The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas.甲状腺微小癌患者在确诊原发性甲状腺癌后发生第二原发癌的风险增加。
Thyroid. 2013 May;23(5):575-82. doi: 10.1089/thy.2011.0406. Epub 2013 Apr 18.
7
The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.甲状腺乳头状癌中 BRAF(V600E) 突变与既定预后因素的关系。
Endocr Pathol. 2012 Sep;23(3):135-40. doi: 10.1007/s12022-012-9218-7.
8
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.RAF 抑制剂与双重 PI3K/mTOR 抑制剂在甲状腺癌中的协同作用。
Clin Cancer Res. 2011 Oct 15;17(20):6482-9. doi: 10.1158/1078-0432.CCR-11-0933. Epub 2011 Aug 10.
本文引用的文献
1
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.三磷酸腺苷竞争型激酶抑制剂在 BRAF 突变型甲状腺癌细胞中的细胞抑制活性。
J Clin Endocrinol Metab. 2010 Jan;95(1):450-5. doi: 10.1210/jc.2009-0373. Epub 2009 Oct 30.
2
Targeting the RAF-MEK-ERK pathway in cancer therapy.在癌症治疗中靶向RAF-MEK-ERK信号通路。
Cancer Lett. 2009 Oct 8;283(2):125-34. doi: 10.1016/j.canlet.2009.01.022. Epub 2009 Feb 12.
3
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.BRAF（V600E）突变与甲状腺乳头状癌患者的预后：一项15年中位随访研究
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9. doi: 10.1210/jc.2008-0607. Epub 2008 Aug 5.
4
Phase II trial of sorafenib in advanced thyroid cancer.索拉非尼用于晚期甲状腺癌的II期试验。
J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9.
5
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.BRAFV600E突变与甲状腺癌细胞系对丝裂原活化蛋白激酶激酶抑制的优先敏感性相关。
J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1.
6
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.丝裂原活化蛋白激酶激酶1/2抑制剂AZD6244对BRAF突变型甲状腺癌的选择性生长抑制作用
J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8. doi: 10.1210/jc.2007-1184. Epub 2007 Sep 18.
7
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.甲状腺乳头状癌中的BRAF突变会抑制参与碘代谢的基因。
J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3. doi: 10.1210/jc.2006-2707. Epub 2007 May 8.
8
BRAF mutation predicts sensitivity to MEK inhibition.BRAF突变预示着对MEK抑制的敏感性。
Nature. 2006 Jan 19;439(7074):358-62. doi: 10.1038/nature04304. Epub 2005 Nov 6.
9
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.BRAF突变预示着甲状腺乳头状癌的临床预后较差。
J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9. doi: 10.1210/jc.2005-0987. Epub 2005 Sep 20.
10
BRAF mutation in papillary thyroid carcinoma.甲状腺乳头状癌中的BRAF突变
J Natl Cancer Inst. 2003 Apr 16;95(8):625-7. doi: 10.1093/jnci/95.8.625.
Zotero 插件